Exciting Results Unveiled for Viva Kompact Dialysis Device
Vivance Concludes Successful Pre-Pivotal Trial
Vivance, a pioneering force in kidney care innovations, has proudly announced the successful conclusion of the next trial phase for its groundbreaking wearable peritoneal dialysis (PD) device, known as Viva Kompact. Conducted at a prominent healthcare facility, this trial represents a significant milestone in the mission to improve kidney care.
Key Achievements of the Viva Kompact Trial
The pre-pivotal trial was designed to evaluate the performance and safety of the Viva Kompact device when used independently by patients in the comfort of their own homes. This innovative device received a breakthrough designation from the US Food and Drug Administration (FDA) in 2019, indicating its potential to change the landscape of kidney treatment positively.
Patient-Centric Results from the Trial
Suresha Venkataraya, the CEO of Vivance, expressed tremendous pride in the accomplishment. He stated, "Completing this trial is a momentous achievement for our team, patients, and healthcare professionals dedicated to advancing kidney care. We are eager to share our findings which we believe will significantly enhance dialysis accessibility for patients."
One of the standout features of the Viva Kompact trial is its focus on real-world application. Ten patients were able to successfully use the device independently for at least one week, marking a considerable achievement without any serious device-related adverse events. This data is crucial for understanding how patients adapt to and benefit from the technology in their daily lives.
Upcoming Presentation at ASN Kidney Week
A/Prof. Marjorie Foo, the Principal Investigator from the Department of Renal Medicine, will present the trial results during oral sessions at the American Society of Nephrology (ASN) Kidney Week. This prestigious event provides an excellent platform for sharing innovative findings with professionals dedicated to improving kidney health.
What to Expect from the Presentation
The presentation is set to delve into critical facets such as the efficacy of the Viva Kompact device, patient experiences, and overall performance data. Insights gained from this trial can profoundly impact future developments in home dialysis technology.
Collaboration and Support for Advanced Kidney Care
Mandar Gori, Chief Business Officer of Vivance, highlighted the collaborative effort involved in making this FDA-designated breakthrough device trial a reality. He expressed gratitude towards clinical advisors and collaborators who played vital roles in advancing kidney care technology.
Attendees of ASN Kidney Week will have the opportunity to learn more about the Viva Kompact device and explore additional innovations at Vivance's booth, enhancing engagement within the kidney care community. This exposure is essential for encouraging discussion about new technologies that will redefine patient care.
About Vivance
Vivance, formerly known as AWAK Technologies, is dedicated to enhancing the lives of individuals living with kidney disease. The company’s mission revolves around providing innovative solutions that aim to improve patient outcomes and life quality.
Headquartered in Singapore, Vivance also operates in locations across the globe, including Los Angeles and Bengaluru. Its commitment to research and development is unwavering as it seeks to introduce novel technologies in kidney care.
For more information about their groundbreaking work and solutions in kidney care, visit their official website.
Frequently Asked Questions
What is the Viva Kompact device?
The Viva Kompact is a wearable peritoneal dialysis device designed to provide patients with greater flexibility and independence in their kidney care treatment.
When will the trial results be shared?
The results from the pre-pivotal trial will be presented during the ASN Kidney Week, which is set to occur from October 23-27.
What were the main findings of the trial?
The trial demonstrated that patients could use the device independently for at least one week without serious adverse events, showcasing its potential for home use.
Who is presenting the trial results?
A/Prof. Marjorie Foo, Principal Investigator, will present the findings focusing on device performance and patient experience.
What is Vivance’s mission?
Vivance aims to enhance the quality of life for patients with kidney disease by developing innovative solutions tailored to their needs.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Oslo OBX Index Gains Amid Mixed Results in Norwegian Stocks
- Exciting New Tar Heel Team Store Opens for UNC Fans
- Hardee's and Special Olympics Virginia Join Forces for a Cause
- Eli Lilly's Mirikizumab Outperforms Johnson & Johnson's Treatment
- NUBURU Cancels Special Meeting: Implications for Investors
- Understanding Wendy's Stock Performance and P/E Ratio
- Transforming $100 Into Over $600: Tenet Healthcare Journey
- Strategic Trading Insights for Key Tech Stocks Today
- Bullish Trends in Options Trading for Coinbase (COIN) Revealed
- Revolutionary HVAC System Promises Green Solutions for Homes
Recent Articles
- Alvarez & Marsal Tax Enhances Restructuring Services with Steinberg
- Husqvarna Welcomes MTE Equipment Solutions to Dealer Family
- Volvo Trucks Unleashes AI for Enhanced Fleet Maintenance Solutions
- AMD Introduces Next-Gen Alveo UL3422 for High-Speed Trading
- Sify Technologies Welcomes Ms. Chunduru to Board as Director
- HL Robotics Expands Horizons with Stanley Robotics Acquisition
- MACH Alliance Elevates Its Role as a Leader in Technology
- Virtual Annual Meeting Set for Reading International Shareholders
- AGCO Plans Third-Quarter 2024 Earnings Call for Investors
- BIO-key Innovates Authentication Solutions at ISC² Security Forum
- Monthly Distribution Announcement from NYLI CBRE Fund for Investors
- Longeveron Presents Groundbreaking Alzheimer's Data at CTAD24
- Exciting Leadership Addition at Sify Technologies Limited
- Society6 Elevates User Experience with Stunning Website Makeover
- Longeveron Presents Key Findings on Lomecel-B at CTAD24
- Trump and Harris: A Tight Presidential Race Analysis
- Greenidge Generation Holds Strong with Q3 2024 Financials
- Triumph Group Faces Challenges Amid Downgrade and Restructuring
- Agillic's Commitment to Data Security and Compliance Audited
- White Cap Enhances Market Presence with ERSCO Acquisition
- Market Overview: Notable Stocks Dip Ahead of Trading
- Citi's Rating Change on Frontier Communications: What It Means
- Adoption of AI and Cloud Technologies Transforming ADM Services
- Jefferies Confirms Hold Rating Amid PENN's Positive Trends
- Red Roof Honors Veterans with Exclusive Discounts Nationwide
- Exploring Promising Tech Stocks Facing Possible Setbacks
- Baird Adjusts Price Target for Lennox International Stocks
- Citigroup's Q3 Earnings Forecast and Analyst Updates
- Clarity Pharmaceuticals Launches Major Prostate Cancer Trial
- Deckers Outdoor Shows Strong Momentum with HOKA Brand Growth
- Barings Facilitates $134M Financing for Smoky Hollow Project
- Bank of America Stock Resilience Amid Buffett's Selloff Shift
- nVent Electric's Positive Outlook: Key Insights for Investors
- Celebrating Remarkable Achievements in Case Management 2024
- AI and Cloud Transformation: Redefining Application Development
- DA Davidson Confirms Buy Rating for JFrog; Strong Financial Growth
- Gerber Childrenswear Unveils Modern Moments Collection on Amazon
- KeyBanc Adjusts Price Target for Reliance Steel & Aluminum
- Engaging Discussions on Sustainable Furnishings at HTD
- Boost Efficiency with Sonic Tools' Latest 182-Piece Kit
- Goldman Sachs Downgrades AutoZone Amid Consumer Concerns
- Marvell Unveils Innovative Custom Ethernet Controller Solution
- J.B. Hunt's Stock Target Upgraded Amid Market Challenges
- Exciting Culinary Adventure: The Shed Restaurant Opens
- Rising Debt Challenges: Countries at Increased Default Risk
- CTi Collaborates with Desmet to Enhance IP Monetization Efforts
- Market Optimism Grows as Fed Rate Cuts Spark 'No Landing' Outlook
- Projected Growth of Biofertilizers Market Reaches $7.10 Billion
- Market Insights: Overview of Recent Trading Trends in Saudi Stocks
- Impact of Bartender Education on Drunk Driving Prevention